Ebhardt H Alexander, Root Alex, Liu Yansheng, Gauthier Nicholas Paul, Sander Chris, Aebersold Ruedi
1Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Auguste Piccard Hof 1, Zürich, Switzerland.
2Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland.
NPJ Syst Biol Appl. 2018 Jul 2;4:26. doi: 10.1038/s41540-018-0064-1. eCollection 2018.
In the United States alone one in five newly diagnosed cancers in men are prostate carcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction pathway are critical in PCa. After initial response to single drugs targeting these pathways resistance often emerges, indicating the need for combination therapy. Here, we address the question of efficacy of drug combinations and development of resistance mechanisms to targeted therapy by a systems pharmacology approach. We combine targeted perturbation with detailed observation of the molecular response by mass spectrometry. We hypothesize that the molecular short-term (24 h) response reveals details of how PCa cells adapt to counter the anti-proliferative drug effect. With focus on six drugs currently used in PCa treatment or targeting the PI3K-AKT-mTOR signal transduction pathway, we perturbed the LNCaP clone FGC cell line by a total of 21 treatment conditions using single and paired drug combinations. The molecular response was analyzed by the mass spectrometric quantification of 52 proteins. Analysis of the data revealed a pattern of strong responders, i.e., proteins that were consistently downregulated or upregulated across many of the perturbation conditions. The downregulated proteins, HN1, PAK1, and SPAG5, are potential early indicators of drug efficacy and point to previously less well-characterized response pathways in PCa cells. Some of the upregulated proteins such as 14-3-3 proteins and KLK2 may be useful early markers of adaptive response and indicate potential resistance pathways targetable as part of combination therapy to overcome drug resistance. The potential of 14-3-3ζ (YWHAZ) as a target is underscored by the independent observation, based on cancer genomics of surgical specimens, that its DNA copy number and transcript levels tend to increase with PCa disease progression. The combination of systematic drug perturbation combined with detailed observation of short-term molecular response using mass spectrometry is a potentially powerful tool to discover response markers and anti-resistance targets.
仅在美国,男性新诊断出的癌症中就有五分之一是前列腺癌(PCa)。雄激素受体(AR)状态和PI3K-AKT-mTOR信号转导通路在前列腺癌中至关重要。在对靶向这些通路的单一药物产生初始反应后,耐药性往往会出现,这表明需要联合治疗。在此,我们通过系统药理学方法解决药物联合疗效以及靶向治疗耐药机制发展的问题。我们将靶向扰动与通过质谱对分子反应的详细观察相结合。我们假设分子短期(24小时)反应揭示了前列腺癌细胞如何适应以对抗抗增殖药物作用的细节。聚焦于目前用于前列腺癌治疗或靶向PI3K-AKT-mTOR信号转导通路的六种药物,我们使用单一和配对药物组合,通过总共21种处理条件对LNCaP克隆FGC细胞系进行扰动。通过对52种蛋白质的质谱定量分析分子反应。数据分析揭示了强反应蛋白的模式,即在许多扰动条件下持续下调或上调的蛋白质。下调的蛋白质HN1、PAK1和SPAG5是药物疗效的潜在早期指标,并指向前列腺癌细胞中以前特征较少的反应通路。一些上调的蛋白质,如14-3-3蛋白质和KLK2,可能是适应性反应的有用早期标志物,并表明作为联合治疗一部分可靶向的潜在耐药通路,以克服耐药性。基于手术标本的癌症基因组学的独立观察强调了14-3-3ζ(YWHAZ)作为靶点具有潜力,即其DNA拷贝数和转录水平往往随着前列腺癌疾病进展而增加。系统的药物扰动与使用质谱对短期分子反应的详细观察相结合,是发现反应标志物和抗耐药靶点的潜在有力工具。